Clinical trials: High-risk Localized Prostate Cancer
Prostate Cancer
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
This is a two-Parallel cohort, prospective study, aimed to explore Efficacy and safety of neoadjuvant Darolutamide with or without ADT in high-risk/very high-risk localized-stage prostate cancer.
- Trial name
- ANDARP (NCT07476677)
- Testing
- Darolutamide, Darolutamide combined with ADT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer
Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer
The purpose of this study is to evaluate the incidence of urinary and rectal acute side effects of a pelvic and prostatic intensity-modulated arctherapy with simultaneous integrated boost (SIB-IMRT)combined with long-term…
- Trial name
- NCT01704027
- Testing
- Simultaneous integrated boost intensity-modulated arctherapy, Androgen deprivation
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Georges Francois Leclerc
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation.
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT05806515
- Testing
- Biospecimen Collection, Carboplatin, Chest Radiography
- Where
- 133 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Localised Prostate Cancer, Locally Advanced Prostate Cancer
MRI Guided Transurethral HIFU for Various Prostate Diseases
This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD).
- Conditions
- Localised Prostate Cancer, Locally Advanced Prostate Cancer, Locally Recurrent Prostate Cancer, Benign Prostatic Hyperplasia
- Trial name
- HIFU-PRO (NCT03350529)
- Testing
- MRI guided transurethral HIFU ablation of prostatic tissue
- Where
- Finland
- Volunteers
- 87 people
- Sponsor
- Turku University Hospital
Malignant Neoplasms of Male Genital Organs, Prostate Cancer
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
The goal of this clinical research study is to learn about biomarker changes in patients who have primary prostate cancer after receiving Darzalex (daratumumab) and then have a prostatectomy (the surgical removal of the prostate)…
- Trial name
- NCT03035357
- Testing
- Daratumumab
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer
RATIONALE: Ultrasound therapy kills tumor cells by heating them to several degrees above body temperature. This treatment may be effective for prostate cancer.
- Trial name
- NCT00005075
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Sponsor
- EDAP Technomed
Prostate Cancer, Prostate Adenocarcinoma
Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes.
Prostate cancer (PCa) is the most prevalent non cutaneous cancer in occidental countries. In Brazil incidence was about sixty thousand new cases in 2016 and occupied second place as all cancer mortality, just behind lung cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Transrectal High Intensity Focused Ultrasound
- Trial name
- NCT03255135
- Testing
- HIFU
- Where
- Brazil
- Volunteers
- 130 people
- Sponsor
- Hospital de Transplante Doutor Euryclides de Jesus Zerbini
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized).
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT04253483
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
- Trial name
- NCT00860158
- Testing
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Noah Hahn, M.D.
High-Risk Localized Prostate Cancer
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6…
- Trial name
- NCT07550517
- Testing
- EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate.
- Trial name
- NCT06798558
- Testing
- Lu-17-PSMA-617
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Hackensack Meridian Health
Prostate Cancer
Preoperative Radiation Therapy for High Risk Prostate Cancer
This is a Phase I dose-escalation study of moderate dose radiation therapy prior to radical prostatectomy for patients with high-risk localized disease.
- Trial name
- NCT01041326
- Testing
- Radiation, Radical Prostatectomy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
High Intensity Focused Ultrasound in Prostate Cancer
This study will investigate the efficacy of focal high intensity focused ultrasound (HIFU) in patients with localized radiorecurrent prostate cancer.
- Trial name
- NCT06402357
- Testing
- Focal One high intensity focused ultrasound device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
Prostate Cancer
Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate
The purpose of the study is to assess the safety of four different doses of radiation therapy followed by to surgery to remove prostate tumor.
- Trial name
- NCT00691977
- Testing
- Radiation Therapy followed by prostatectomy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Prostate Cancer
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate…
- Trial name
- NeoPSMA (NCT06881823)
- Testing
- AAA602, AAA802, Gallium (68Ga) gozetotide
- Sponsor
- Novartis Pharmaceuticals